You are here

Commercialisation

In order to realise the full potential of promising drug discoveries, we tailor our services and recommendations to suit the individual needs of each project. This flexible approach to commercialisation enables us to work with a diverse range of commercial and academic organisations.

We've established major partnerships with research institutions, pharmaceutical companies and biotechnology companies of all sizes so we have a unique understanding of both the academic and industry perspective and the ability to facilitate productive, mutually beneficial alliances.

Such partnerships are crucial in progressing drugs through the latter stages of clinical development and regulatory approval - bringing breakthrough therapeutics to cancer patients sooner.

  • LICENSING AND SPIN-OUTS

    One of the most common commercialisation routes is the grant of a licence to a commercial partner. CRUK has a broad portfolio of cancer-focused projects available for licensing or co-development; we complete around 50 licensing or collaboration agreements each year.

    Where technologies with a broad application can be most effectively advanced via a focused and innovative environment, CRUK will stimulate the creation of a start-up company. We've been involved in the formation of over 44 start-ups - some of which have achieved significant exits through acquisition by leading pharmaceutical companies.

  • COLLABORATION

    The Cancer Research UK Commercial Partnerships team is uniquely placed to capitalise on the strong links we’ve established with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide. Recent collaborations include:

    • In October 2019, the Cancer Research UK Beatson Institute entered into a multi-year collaboration with Novartis to continue the development of KRAS inhibitors, first discovered by the Institute. This builds on a collaboration begun in 2017 between Cancer Research UK, the Cancer Research Technology Pioneer Fund (managed by Sixth Element Capital) and the US's National Cancer Institute (NCI) to develop gold standard tests to analyse these novel RAS inhibitors. Read more.
    • Cancer Research UK, LifeArc and Ono Pharma entered a multimillion-pound immunotherapy drug discovery alliance in March 2019, building on a 2017 target discovery and validation alliance between Cancer Research UK and LifeArc (originally MRC Technology). Read more.
    • Cancer Research UK, UCL, and Tusk Therapeutics first entered a licence and collaboration agreement in 2017 to research, develop and commercialise an antibody-based therapeutic against the Interleukin-2 receptor alpha chain CD25 (IL-2Rα), a target that plays a key role in immune suppression in cancer.  Roche, who acquired Tusk in late 2018, has continued this collaboration and is now running a phase 1 trial in solid tumours of the monoclonal antibody developed under the collaboration, RG6292. Read more.

     

     

  • ALLIANCES

    Rather than investing in high-risk, early drug discovery themselves, pharmaceutical companies are increasingly looking to external organisations to provide multiple promising projects to take forward over a themed area of biology.

    This approach facilitates the low-risk exploration of novel broad areas of science with the potential to yield multiple commercially attractive projects. Such alliances combine the individual strengths of academic research and drug discovery and pharma clinical development and have the potential to deliver patient benefit.

    CRUK Therapeutic Discovery laboratories have established major multi-project alliances with AstraZeneca, Teva Pharmaceuticals, FORMA Therapeutics, Merck KGaA, and LifeArc (formerly MRCT).

     

    Related links

  • CONSORTIA

    Early Diagnosis

    Commercial Partnerships supports CRUK's efforts to involve industry partners in its International Alliance for Cancer Early Detection (ACED).

LICENSING AND SPIN-OUTS Open

One of the most common commercialisation routes is the grant of a licence to a commercial partner. CRUK has a broad portfolio of cancer-focused projects available for licensing or co-development; we complete around 50 licensing or collaboration agreements each year.

Where technologies with a broad application can be most effectively advanced via a focused and innovative environment, CRUK will stimulate the creation of a start-up company. We've been involved in the formation of over 44 start-ups - some of which have achieved significant exits through acquisition by leading pharmaceutical companies.

Related links

COLLABORATION Open

The Cancer Research UK Commercial Partnerships team is uniquely placed to capitalise on the strong links we’ve established with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide. Recent collaborations include:

  • In October 2019, the Cancer Research UK Beatson Institute entered into a multi-year collaboration with Novartis to continue the development of KRAS inhibitors, first discovered by the Institute. This builds on a collaboration begun in 2017 between Cancer Research UK, the Cancer Research Technology Pioneer Fund (managed by Sixth Element Capital) and the US's National Cancer Institute (NCI) to develop gold standard tests to analyse these novel RAS inhibitors. Read more.
  • Cancer Research UK, LifeArc and Ono Pharma entered a multimillion-pound immunotherapy drug discovery alliance in March 2019, building on a 2017 target discovery and validation alliance between Cancer Research UK and LifeArc (originally MRC Technology). Read more.
  • Cancer Research UK, UCL, and Tusk Therapeutics first entered a licence and collaboration agreement in 2017 to research, develop and commercialise an antibody-based therapeutic against the Interleukin-2 receptor alpha chain CD25 (IL-2Rα), a target that plays a key role in immune suppression in cancer.  Roche, who acquired Tusk in late 2018, has continued this collaboration and is now running a phase 1 trial in solid tumours of the monoclonal antibody developed under the collaboration, RG6292. Read more.

 

 

Related links

ALLIANCES Open

Rather than investing in high-risk, early drug discovery themselves, pharmaceutical companies are increasingly looking to external organisations to provide multiple promising projects to take forward over a themed area of biology.

This approach facilitates the low-risk exploration of novel broad areas of science with the potential to yield multiple commercially attractive projects. Such alliances combine the individual strengths of academic research and drug discovery and pharma clinical development and have the potential to deliver patient benefit.

CRUK Therapeutic Discovery laboratories have established major multi-project alliances with AstraZeneca, Teva Pharmaceuticals, FORMA Therapeutics, Merck KGaA, and LifeArc (formerly MRCT).

 

Related links

CONSORTIA Open

Early Diagnosis

Commercial Partnerships supports CRUK's efforts to involve industry partners in its International Alliance for Cancer Early Detection (ACED).

Related links